Myeloma Minute: Making Myeloma Matter


| EDUCATION | Diversity


Making Myeloma Matter

Did you know that black men and women are diagnosed with myeloma at approximately twice the rate as the combined average for all ethnic backgrounds? Unfortunately, we don’t yet know the reasons for these rates. The African American community needs access to resources to better recognize symptoms, understand their diagnosis, and research treatment options for this disease. That’s why the International Myeloma Foundation has launched a mailing list at Sign up so that you can be the first to know of any new developments, studies, or programs that may affect you and your loved ones in the African American community.


| INSPIRATION | Myeloma Voices




From Overwhelmed Myeloma Patient to Support Group Leader
Register NOW for a Regional Community Workshop in Birmingham, Alabama

Diagnosed with multiple myeloma in 2012, Frank Morelli shares how he and his wife Debbie went from being overwhelmed with their own situation to helping others at their support group. Listen to hear sentiments such as this one: “I understand that [at the] next doctor appointment, things could be traumatically different. I think that’s what’s important about understanding myeloma. Also, it’s part of your education, and the benefit of being part of the support group and the information that we get from people like the IMF. You’re prepared.”

The IMF will conduct a Regional Community Workshop in Birmingham, AL, on Saturday, October 6, 2018. Registration is FREE, but seating is limited. This is a wonderful opportunity to learn from and meet one-on-one with myeloma experts Luciano J. Costa, MD, PhD (Associate Professor of Medicine, University of Alabama at Birmingham), Kelly Godby, MD (Assistant Professor of Medicine, UAB Hematology/Oncology, University of Alabama at Birmingham), and Charise Gleason, MSN, NP-BC, AOCNP (Winship Cancer Institute, Emory University, Atlanta).


Register Now Button.png

| INNOVATION | Drug Development


Daratumumab Approved in Europe for First-line Treatment of Patients with Multiple Myeloma

The European Commission has granted approval of Darzalex® (daratumumab), a CD38-directed antibody, for first-line treatment of patients with multiple myeloma. The approval authorizes the use of Darzalex in combination with Velcade® (bortezomib), melphalan, and prednisone (VMP), for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). This approval is based on results of the phase III ALCYONE (MMY3007) study.


| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series



BOSTON Trial Fact Sheet

New isatuximab Clinical Trial: the IMROZ Study

New isatuximab Clinical Trial: the IKEMA Study

New ixazomib Clinical Trials: Learn How to Participate

Join the conversation about myeloma on the Smart Patients Message Board

September 8, 2018
IMF Regional Community Workshop
Richmond, VA

September 15, 2018
IMF Regional Community Workshop
Columbus, OH

September 22, 2018
6th Annual Miracles for Myeloma 5K Race/Walk
Oak Ridge Park Clark, NJ

September 22, 2018
IMF Regional Community Workshop
Overland Park, KS

September 22, 2018
A Mission for Matt
Mineola, NY

September 22, 2018
Sixth Annual Wine-Tasting Tour

September 23, 2018
Fourth Annual Walk-a-Thon/BBQ to End Myeloma
Flushing Meadows Park, NY

subscribe_button.png          donate_button_bottom.png
We Thank Our Sponsors:
Amgen, Celgene Corporation, Genentech, Janssen Oncology, and Takeda Oncology
and individuals like you who supported the IMF this year

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.